ClinicalTrials.gg
RecruitingNCT07578480Updated May 11, 2026

MEN-ENDO: Menstrual Stem Cells in Endometriosis

An observational study in Endometriosis, sponsored by Francisco Algaba Chueca. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Francisco Algaba Chueca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Endometriosis with a site in Spain — 13 open to participants now, 15 under way, none of them phase 3. Endometriosis · Spain.

Started
2026
with 2 others
Observational
8 of 42
5 open now
Primary completion
2027-10
later than 12 of 14 live
Registered
42nd of 42
by date

Among the 42 studies in Endometriosis with a site in Spain, this one is one of 3 that started in 2026, is one of 8 observational ones, reaches primary completion later than 12 of the 14 other live ones, and was the 42nd registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

13 of the 42 studies in Endometriosis with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Endometriosis with a site in Spain, or all of them as a file.
02

Study summary

Endometriosis is a chronic inflammatory condition characterized by the presence of endometrium-like tissue outside the uterine cavity. It is estimated to affect approximately 10% of women of reproductive age and it is associated with chronic pelvic pain and infertility, among other symptoms.

Endometriosis involves complex changes in the body's cells and immune response. For this reason, the goal of this observational study is to characterize the functional, molecular, and immunological alterations in menstrual blood-derived stem cells (MenSCs) and differentiated decidual stromal cells in women with endometriosis; to validate these findings in endometrial tissue and endometriomas; and to establish their correlation with clinical parameters, with the aim of identifying key pathogenic mechanisms and potential therapeutic targets.

The main questions it aims to answer are:

  • Are there functional and molecular changes in MenSCs from patients with endometriosis compared to healthy volunteers?
  • Are there any variations in the immune properties of MenSCs throughout the menstrual bleeding period in patients with endometriosis compared to healthy volunteers?
  • Are these changes also present in endometrial tissue and endometrioma samples?
  • Can these changes be correlated with clinical parameters in patients with endometriosis?
  • Can MenSCs serve as a potential therapeutic target for endometriosis?

Some participants will be asked to provide menstrual blood on a single day, while others will provide samples during the first five days of menstruation. Additionally, all participants will answer questionnaires about their diet, physical activity, stress, and pain levels. Therefore, the study does not involve the evaluation of a specific intervention on the participants.

The results will enable the identification of key altered mechanisms and potential therapeutic targets, thereby contributing to the development of more effective strategies for the diagnosis and treatment of the disease.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Menstrual blood-derived stem cells
  • Menstrual blood
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Our study population consists of 40 women aged between 18 and 45, 20 of whom have been diagnosed with endometriosis and 20 of whom are healthy volunteers. Participants will be recruited from the Department of Gynecology and Obstetrics at the Hospital Universitari Joan XXIII in Tarragona (Spain) during routine gynecological check-ups. Healthy volunteers will be selected through individual matching with participants in the study group, considering relevant demographic and clinical variables such as age and ethnic group.

In addition, a sub-cohort of 10 women (5 per study group) will be selected from the main cohort to study in greater detail the intra-menstrual variations in the immunomodulatory properties of MenSCs. This sub-cohort will include participants who agree to provide menstrual blood samples from days 1 to 5 (both inclusive) to analyze dynamic changes in the cells obtained, while maintaining the same general inclusion and exclusion criteria as in the main study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-45 years.
  • Endometriosis group: Women with clinical and/or ecographical diagnostic of endometriosis.
  • Control group: Women with the endometriosis diagnosis.

Exclusion criteria

Exclusion Criteria:

  • \<18 years or >45 years.
  • Pregnancy or lactation.
  • Diagnosis of prior chronic pelvic inflammatory or disease.
  • History of active gynecological cancer.
  • Positive for (HIV) or human papillomavirus (HPV).
  • Hormonal therapy use in the previous 3 months.
  • Use of or in the previous 3 months.
  • Systemic antibiotics use in the previous 3 months.
  • Insufficient menstrual flow to allow the MenSCs isolation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Endometriosis

    Other: Menstrual blood-derived stem cells collection and in vitro characterization

Interventions

  • OtherMenstrual blood-derived stem cells collection and in vitro characterization

    Menstrual-blood derived stem cells will be isolated from the menstrual blood of patients with endometriosis and healthy volunteers to be characterized in vitro.

06

What researchers measure

Primary outcomes

  1. MenSCs proliferation rate

    Evaluation of the expansion capacity of MenSCs from endometriosis patients vs. healthy controls using the MTT assay.

    Time frame: Through study completion (average of 3 years)

  2. Phenotypic characterization of MenSCs

    Evaluation of surface marker expression using flow cytometry to determine the phenotype of MenSCs from endometriosis patients and healthy controls.

    Time frame: Through study completion (average of 3 years).

  3. MenSC chemotaxis

    Assessment of the number of T-lymphocytes and monocytes capable of migrating through a transwell membrane under the stimuli of conditioned media from MenSCs obtained from endometriosis patients and healthy controls.

    Time frame: Through study completion (average of 3 years)

  4. MenSC invasion capacity

    Assessment of the number of MenSCs from endometriosis patients vs. healthy controls capable of degrading a Matrigel on a transwell membrane and migrating toward a chemoattractant.

    Time frame: Through study completion (average of 3 years)

  5. Multilineage capacity of MenSCs

    The differentiation potential of MenSCs from endometriosis patients vs. healthy controls towards osteocytes, chondrocytes and adipocytes will be assessed by using specific media.

    Time frame: Through study completion (average of 3 years)

  6. Decidualitzation response to progesterone of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers

    MenSCs will be cultured in presence of 8-Br-cAMP during 14 days, and the assessment of morphology and expression of decidual markers will be performed by RT-qPCR and ELISA assay.

    Time frame: Through study completion (average of 3 years).

  7. Apoptosis resistance assessment of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers

    Apoptosis resistance will be evaluated by Annexin V/PI flow cytometry following induction by TNFα. Additionally, the expression of key apoptotic mediators will be quantified using RT-qPCR and Western blot.

    Time frame: Through study completion (average of 3 years).

  8. Cytokine profile of the secretome of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells.

    The conditioned media will be assessed to determine the cytokines secreted using an ELISA assay.

    Time frame: Through study completion (average of 3 years).

  9. Cytokine profile of the endometrial and endometrioma tissues

    The levels of cytokines in the conditioned media from cultured explants will be assessed by ELISA assay.

    Time frame: Through study completion (average of 3 years).

  10. Cytokine profile of the secretome of immune cells populations

    The levels of cytokines in the conditioned media from lymphocytes and macrophages will be assessed by ELISA assay.

    Time frame: Through study completion (average of 3 years)

  11. Cytokine profile of the peripheral blood plasma

    The levels of cytokines in peripheral blood plasma from endometriosis patients and healthy volunteers will be determined by ELISA assay.

    Time frame: Through study completion (average of 3 years)

  12. Gene expression profile of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells

    Total RNA expression of targeted genes will be analyzed by RT-qPCR.

    Time frame: Through study completion (average of 3 years)

  13. Gene expression profile of the endometrial and endometrioma tissues

    Total RNA expression of targeted genes will be analyzed by RT-qPCR.

    Time frame: Through study completion (average of 3 years).

  14. Gene expression profile of the immune cells populations

    Total RNA expression of targeted genes will be analyzed by RT-qPCR.

    Time frame: Through study completion (average of 3 years)

  15. Protein expression of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells

    Analysis of the protein expression profile via Western Blot.

    Time frame: Through study completion (average of 3 years)

  16. Protein expression in endometrial and endometrioma tissues

    Analysis of the protein expression profile via Western Blot.

    Time frame: Through study completion (average of 3 years)

  17. Protein expression in immune cells populations

    Analysis of the protein expression profile via Western Blot.

    Time frame: Through study completion (average of 3 years)

  18. T cells activation

    T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients. Afterwards, the levels of IL-10 and IFNy will be determined by ELISA assay.

    Time frame: Through study completion (average of 3 years)

  19. T cells proliferation rate

    T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients. Afterwards, their proliferative capacity will be assessed by MTT assay.

    Time frame: Through study completion (average of 3 years)

  20. Cytokine secretion profile of macrophages

    The levels of cytokines in the supernatant of polarized macrophages after incubation with MenSC-derived conditioned media from endometriosis patients and healthy volunteers will be determined by ELISA assay.

    Time frame: Through study completion (average of 3 years)

  21. Gene expression profile of macrophages

    Total RNA expression of targeted genes will be analyzed by RT-qPCR.

    Time frame: Through study completion (average of 3 years)

  22. Protein expression of macrophages

    Analysis of the protein expression profile via Western Blot.

    Time frame: Through study completion (average of 3 years)

  23. Phagocytic capacity of macrophages

    Assessment of the macrophages' ability to engulf fluorescently labeled apoptotic bodies from MenSCs via flux cytometry and fluorescence microscopy.

    Time frame: Through study completion (average of 3 years)

  24. Angiogenic potential of macrophages conditioned media

    Evaluation of the ability of macrophage-derived conditioned media to induce tube formation (Matrigel) in Human Umbilical Vein Endothelial Cells (HUVECs).

    Time frame: Through study completion (average of 3 years)

  25. Exploration of targeted interventions to reverse the pathological phenotype of MenSCs and macrophages derived from menstrual blood.

    Signaling pathways and genes involved in the altered phenotype will be blocked and silenced, respectively, to evaluate if these actions reverse the cellular response to the levels of the healthy volunteers' cells.

    Time frame: Through study completion (average of 3 years).

  26. Correlation of cellular, tissue and molecular findings with patients' clinical parameters.

    The associations among the functional and immunological properties of MenSCs and macrophages, clinical parameters and dietary and behavioral habits will be stablished. These clinical parameters include endometriosis stage, pain and fertility status, and the extent and localization of the endometriosis foci.

    Time frame: Through study completion (average of 3 years).

07

Study locations

1 of 2 sites recruiting
  • Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut
    Reus, Tarragona 43201, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Universitari Joan XXIII
    Tarragona, Tarragona 43005, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Oct 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
May 11, 2026
StartEst.
Apr 2026
Primary completionEst.
Oct 2027
CompletionEst.
Apr 2028
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07578480
Lead sponsor
Francisco Algaba Chueca
Collaborators
Hospital Universitari Joan XXIII de Tarragona.
Responsible party
Francisco Algaba Chueca (Senior Lecturer, University Rovira i Virgili) — Sponsor-investigator
First posted
May 11, 2026
Start date
Apr 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
May 11, 2026

Study contacts

Dr. Francisco Algaba-Chueca
Contact
francisco.algaba@urv.cat
+34623966066
Dr. Victoria Linares-Vidal
Contact
mvictoria.linares@urv.cat
+34977759374

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion